Record Nr.	UNINA9910633973203321
Titolo	The global antimicrobial resistance epidemic : Innovative Approaches and Cutting-Edge Solutions / / edited by Guillermo Tellez-Isaias
Pubbl/distr/stampa	London : , : IntechOpen, , 2022
ISBN	1-80356-042-8
Descrizione fisica	1 online resource (264 pages)
Disciplina	616.9041
Soggetti	Drug resistance in microorganisms
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Nota di contenuto	 Introductory Chapter: The Antibiotic Resistance Epidemic 2. Honey as a Natural Product Worthy of Re-Consideration in Treating MRSA Wound Infections 3. Unlocking the Potential of Ghost Probiotics in Combating Antimicrobial Resistance 4. Managing Antimicrobial Resistance beyond the Hospital Antimicrobial Stewardship: The Role of One Health 5. Molecular Tools for the Study of Resistance to Disinfectants 6. Worldwide Colistin Use and Spread of Resistant-Enterobacteriaceae in Animal Production 7. Use of Humic Substances from Vermicompost in Poultry 8. Pyoverdine as an Important Virulence Factor in Pseudomonas aeruginosa Antibiotic Resistance 9. Machine Learning for Antimicrobial Resistance Research and Drug Development 10. Carriage of Beta-Lactamase and Antibiotic Resistance in Staphylococcus aureus 11. Alternatives to Antibiotics in Semen Extenders Used in Artificial Insemination 12. Quorum Sensing Inhibition Based Drugs to Conquer Antimicrobial Resistance 13. Acinetobacter baumannii: Emergence of a Superbug, Past, Present, and Future 14. Efflux Pumps among Urinary E. coli and K. pneumoniae Local Isolates in Hilla City, Iraq.
Sommario/riassunto	Antibiotic resistance is a global health crisis. Misuse of antibiotics in humans, animals, food, and agriculture has compounded the situation. Bacterial infections have returned decades after medicines were first used. This book discusses antibiotic resistance and some of the organisms that pose immediate, serious, and alarming dangers. It highlights the need for a broader, more comprehensive approach to

1.

techniques (other than sta or the host, such as antibo	s, which may involve non-compound indard antibacterial drugs) that target bacteria odies, probiotics, phytobiotics, and
vaccinations.	